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Malaria is one of the most important tropical para-
sitic diseases in humans, causing great morbidity and 
mortality in tropical regions with 300-500 million clini-
cal cases and approximately one million deaths per year 
(WHO 2010). Human malaria is caused by five species 
of the Plasmodium parasites, namely Plasmodium fal-
ciparum, Plasmodium vivax, Plasmodium ovale, Plas-
modium malariae and Plasmodium knowlesi (Cox-Singh 
& Singh 2008). P. falciparum is responsible for the vast 
majority of malaria-related deaths (Snow et al. 2005). 
The global expansion of the disease has been attributed 
mainly to the failure of vector control programs, the ab-
sence of a vaccine and the increase in parasite resistance 
to drugs commonly used for therapy. As a result, the 
discovery and development of new and effective anti-
malarial agents is imperative. This aim can be achieved 
in three ways: (i) by focusing on previously validated 
parasite targets to generate new drug candidates, (ii) by 
identifying new potential parasite targets for malaria 
chemotherapy (Ridley 2002) or (iii) by performing high-
throughput testing of drug libraries (Guiguemde et al. 
2010). With many malaria parasite genome-sequencing 
projects now complete, efforts are being directed to-
wards a better understanding of gene functions and the 
discovery of new drug targets (Gardner et al. 2002).
The phylum Apicomplexa harbours a relict plastid 
known as the apicoplast (McFadden et al. 1996); its dis-
covery brought about an exciting new prospect for drug 
development against P. falciparum (Jomaa et al. 1999, 
Lim & McFadden 2010). The apicoplast possesses four 
membranes; therefore, it is hypothesised to be the re-
sult of a secondary endosymbiosis, which means that, at 
some point, the parasite engulfed another eukaryote that 
contained a plastid obtained by primary endosymbiosis 
of a cyanobacterium-like prokaryote (Funes et al. 2002, 
Moore et al. 2008). The apicoplast genome is clearly re-
lated to the plastid genome of plants and algae but has a 
greatly reduced sequence complexity and lacks the genes 
that encode proteins involved in photosynthesis. Be-
cause the structure of the apicoplast was retained in the 
parasite, it is thought to have an important function for 
the parasite’s survival (Sullivan et al. 2000). A predicted 
apicoplast proteome has been assembled and putative 
pathways for the biosynthesis of fatty acids, isoprenoids, 
iron-sulphur clusters and haem have been mapped to the 
apicoplast. These metabolic pathways are distinct from 
the pathways found in the mammalian host, although 
which of these pathways make the apicoplast indispen-
sable remains to be elucidated (Ralph et al. 2004).
Isoprenoids - With more than 23,000 primary and 
secondary metabolites, isoprenoids form the most diverse 
and abundant group of organic compounds in nature. 
They are derived from branched C5 isoprenoid units. The 
number of repetitions of this motif, cyclisation reactions, 
rearrangements and further oxidation of the carbon skel-
eton are responsible for the enormous structural diversity 
(Connolly & Hill 1992). Many types of isoprenoids (ste- 
roids, cholesterol, retinoids, carotenoids, ubiquinones and 
prenyl groups bound to proteins) are essential components 
of the cellular machinery that are found in all organisms. 
They participate in a variety of biological processes: (i) 
carotenoids, chlorophyll and plastoquinone are essential 
constituents of the photosynthetic apparatus; (ii) ubi- 
quinone, menaquinone (MQ) and plastoquinone are em-
ployed as electron carriers required for the mitochondrial 
respiratory chain; (iii) prenylated proteins, including Ras 
and Rho GTPases, function as signal transducers; (iv) 
dolichols participate in the post-translational modifica-
tion of proteins, an event that is involved in tumour cell 
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growth and differentiation and cellular signalling (Wang 
& Ohnuma 1999); (v) phosphorylated dolichols have a 
role as carriers of oligosaccharides in the biosynthesis of 
glycoproteins and glycosylphosphatidyl inositol anchors 
(Burda & Aebi 1999, Spiro 2002).
Isoprenoids vary greatly in size but are all synthe-
sised from a common building block, the isoprene unit 
isopentenyl diphosphate (IPP) and its isomer dimethylal-
lyl diphosphate (DMAPP). Two distinct and independent 
pathways exist that biosynthesise IPP: the classical me-
valonate pathway and a mevalonate-independent meth-
ylerythritol phosphate (MEP) pathway.
The mevalonate pathway - Bloch (1958) and Ly-
nen (1958) first described the mevalonate pathway 
in animals and yeast revised by Spurgeon and Porter 
(1981). For several decades, the mevalonate pathway 
was considered the only biosynthetic route leading to 
IPP and DMAPP. This pathway uses seven enzymes to 
supply the precursors in most eukaryotes (all mammals) 
and in archae bacteria, eubacteria, algae (except chlo-
rophytes), higher plants, bryophytes and some protozoa 
such as Trypanosoma and Leishmania (Goldstein & 
Brown 1990). This pathway starts with a reaction cataly-
sed by a thiolase that produces acetoacetyl-CoA from 
two molecules of acetyl-CoA. A third acetyl-CoA is then 
condensed with acetoacetyl-CoA to form 3-hydroxy-3-
methylglutaryl-CoA (HMG-CoA) by HMG-CoA syn-
thase. The NADPH-dependent HMG-CoA reductase 
then converts the CoA-bound compound to mevalonic 
acid (MVA). Next, MVA is sequentially phosphorylated 
by the mevalonate and diphosphomevalonate kinases to 
form MVA-5-diphosphate. This diphosphate is subse-
quently decarboxylated by mevalonate diphosphate de-
carboxylase to yield a pool of IPP, which is then convert-
ed to DMAPP by an IPP isomerase. The enzymes of the 
mevalonate pathway have been studied from a number 
of organisms, including humans. HMG-CoA reductase, 
the best-characterised and rate-limiting enzyme in the 
pathway, is the target of the statin class of cholesterol-
lowering drugs (Alberts et al. 1980). Whereas the me-
valonate pathway in bacteria was previously thought to 
be due to horizontal gene transfer from other domains, 
Lombard and Moreira (2011) demonstrated using phylo-
genetic analyses that the mevalonate pathway is likely 
ancestral not only in archaea and eukaryotes but also 
in bacteria. The authors concluded that the mevalonate 
pathway is likely an ancestral metabolic route in all three 
domains of life and was probably present in the last com-
mon ancestor of all organisms.
The MEP pathway - The MEP pathway was first de-
scribed in eubacteria (Rohmer et al. 1993) followed by 
several photosynthetic organisms such as cyanobacteria 
(Cvejic & Rohmer 2000), algae (Disch et al. 1998) and 
higher plants (Rohmer 1999). Later, it was described in 
apicomplexan parasites (Jomaa et al. 1999) and Myco-
bacterium tuberculosis (Bailey et al. 2002). It was also 
found in several pathogenic eubacteria but not in animals 
or archae bacteria (Lichtenthaler 2000). The initial step, 
catalysed by 1-deoxy-D-xylulose-5-phosphate (DOXP) 
synthase, is the formation of DOXP by the condensa-
tion of pyruvate and glyceraldehyde-3-phosphate. The 
dxp gene encoding this enzyme was first cloned from 
Escherichia coli (Lois et al. 1998). This key enzyme of 
the pathway requires thiamine diphosphate and divalent 
cations such as Mg2+ or Mn2+ for its activity. The enzyme 
DOXP reductoisomerase catalyses the rearrangement 
and subsequent reduction of DOXP to MEP. The activity 
of this enzyme is inhibited by fosmidomycin (Kuzuyama 
et al. 1998). MEP is then converted to 4-(cytidine-5-
diphospho)-2-C-methyl-D-erythritol (CDP-ME) in a cy-
tosine triphosphate-dependent reaction by the ispD gene 
product CDP-ME synthase. The next step is catalysed 
by the enzyme CDP-ME kinase and leads to the phos-
phorylation of CDP-ME. The product of this reaction, 
4-(cytidine-5-diphospho)-2-C-methyl-D-erythritol-2-
phosphate (CDP-MEP-2P), is subsequently converted 
to 2-C-methyl-D-erythritol-2,4-cyclodiphosphate (ME- 
2,4-cPP) by the enzyme 2-C-methyl-D-erythritol 2,4-
cyclodiphosphate synthase. IPP and DMAPP are synthe-
sised through independent routes in the last steps of the 
MEP pathway (Lichtenthaler 2000). Additionally, the 
MEP pathway produces the precursor (DOXP) for the 
synthesis of the essential cofactors thiamine diphosphate 
and pyridoxal phosphate (Sprenger et al. 1997).
In the following section, we address the recent ad-
vances that were made by our group regarding the syn-
thesis of downstream products of the MEP pathway in 
P. falciparum and the exploitation of these pathways as 
potential novel drug targets (Figure).
MEP pathway in P. falciparum - Various attempts 
to provide evidence for the existence of the mevalonate 
pathway in Plasmodium have led to ambiguous results. 
To characterise the presence of the mevalonate path-
way, [3H] mevalonolactone or (RS)-[5-3H]-mevalonate is 
commonly used to perform metabolic labelling (Gold-
stein & Brown 1990). Unfortunately, all efforts to label 
isoprenoid constituents with these precursors in P. falci-
parum were unsuccessful. However, upon incubation of 
extracts from P. falciparum infected red blood cells with 
[14C] mevalonate, Mbaya et al. (1990) identified farnesyl 
pyrophosphate. Metabolic labelling of in vitro cultured 
parasites using [3H] mevalonolactone was performed to 
analyse dolichols and ubiquinones, but no products were 
identified (AM Katzin et al., unpublished observations). 
Inhibitors (lovastatin and simvastatin) of HMG-CoA re-
ductase interfered with the in vitro development of P. 
falciparum, but only at high, pharmacologically irrel-
evant, concentrations (Grellier et al. 1994). Accordingly, 
no HMG-CoA reductase activity was detectable above 
background levels in extracts from P. falciparum and P. 
knowlesi (Vial et al. 1984).
Clastre et al. (2007) demonstrated that the MEP path-
way was also active in other apicomplexan parasites, 
namely Eimeria tenella and Toxoplasma gondii. Addi-
tionally, transcription profiles confirmed that MEP path-
way-related genes were transcribed in these parasites. In-
triguingly, BLAST analysis showed that Cryptosporidium 
parvum and Cryptosporidium hominis lack both the MVA 
and MEP pathways. However, these species contain or-
thologs of prenyltransferases, suggesting that isoprenoid 
precursors perhaps may be acquired from the host.
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In Plasmodium, the apicoplast is the only site of 
isoprenoid precursor synthesis. Jomaa et al. (1999) 
demonstrated that a recombinant P. falciparum DOXP 
reductoisomerase, which converts DOXP to MEP, was 
enzymatically active and could be inhibited by fosmid-
omycin. The authors also demonstrated that fosmidomy-
cin and its derivative FR900098 are able to inhibit the 
growth of P. falciparum in culture and suppress the in 
vitro growth of multidrug-resistant P. falciparum strains. 
Moreover, mice infected with the rodent malaria parasite 
Plasmodium vinckei were cured after treatment with fos-
midomycin. However, FR900098 was found to be twice 
as effective as fosmidomycin. In the same work, the au-
thors showed that an amino-terminal signal sequence 
in DOXP reductoisomerase targeted the enzyme to the 
apicoplast. In addition, DOXP reductoisomerase activity 
could be detected in crude and partially purified protein 
extracts from P. falciparum using a sensitive functional 
assay (Wiesner et al. 2000).
Recently, it was demonstrated that fosmidomycin di-
rectly inhibits its known target, DOXP reductoisomerase, 
and indirectly acts upon cells to inhibit a second target, the 
downstream enzyme MEP cytidyltransferase (Zhang et 
al. 2011). Umeda et al. (2010) obtained crystallised DOXP 
reductoisomerase from P. falciparum and preliminary X-
ray crystallographic and structural analyses by molecular 
replacement are in progress. Rohdich et al. (2001) charac-
terised the recombinant enzyme 2-C-methyl-D-erythritol 
2,4-cyclodiphosphate synthase in P. falciparum. Finally, 
Ralph et al. (2004) suggested the presence of several MEP 
pathway-related genes in P. falciparum, all of which pos-
sess apicoplast-targeting sequences, indicating that the 
DOXP pathway is localised in the apicoplast.
Cassera et al. (2004) showed by metabolic labelling 
with [1-14C]acetate, D-[U-14C]glucose and [2-14C]DOXP 
that the MEP pathway is functionally active in the intraer-
ythrocytic stages of P. falciparum. This group identified 
all but one of the intermediates of the MEP pathway us-
ing high-performance liquid chromatography and mass 
spectrometric analyses. The identified intermediates 
were DOXP, MEP, CDP-ME, CDP-MEP-2P and ME- 
2,4-cPP (Figure). The effect of fosmidomycin on levels of 
the MEP pathway intermediates was found to be the most 
prominent in ring stages and only minor inhibitory effects 
were observed in the trophozoite and schizont stages, re-
flecting differences in the drug sensitivity of the parasite 
blood forms. Cassera et al. (2004) also showed that the 
MEP pathway provides precursors for the synthesis of 
ubiquinone and dolichol. This result was demonstrated 
by the decrease in the ubiquinone and dolichol content in 
fosmidomycin-treated parasites. Because fosmidomycin 
inhibits the DOXP reductoisomerase and kills malaria 
parasites, the biosynthesis of isoprenoids has been pre-
sumed to be essential in Plasmodium.
Interestingly, and similar to effects observed for the 
inhibition of plasmodial dihydrofolate reductase (Zhang 
& Rathod 2002), no alteration in the transcription of 
MEP pathway-related genes was found (Cassera et al. 
2007), suggesting that there is no feedback control of 
transcription exerted by metabolites of the MEP path-
way as is often found in other organisms. Surprisingly, 
fosmidomycin had only a small effect on the growth of 
either E. tenella or T. gondii in vitro, even at higher con-
centrations, suggesting that the drug either is not equally 
active or its uptake varies in different apicomplexan par-
asites (Clastre et al. 2007).
Thus far, all genes related to the MEP pathway have 
been identified in the P. falciparum genome, but only 
three genes that encode the enzymes DOXP synthase, 
DOXP reductoisomerase and 2-C-methyl-D-erythritol-
2,4-cyclodiphosphate synthase have been functionally 
characterised. Due to their absence in human cells, en-
zymes from the MEP pathway are excellent molecular 
targets for the development of new antimalarial drugs. 
Field trials in humans have also demonstrated the ef-
fectiveness of fosmidomycin in the treatment of human 
malarial infections (Borrmann et al. 2005, 2006). Re-
cent clinical studies showed that fosmidomycin was ef-
fective and well tolerated in the treatment of patients 
with acute uncomplicated P. falciparum malaria but, 
unfortunately, resulted in an unacceptably high rate of 
recrudescence (Wiesner et al. 2002).
Biosynthesis of isoprenoids in P. falciparum - The 
first reports demonstrating the biosynthesis of isopre-
noids in Plasmodium were published by Rietz et al. 
(1967) and Skelton et al. (1969), showing the occur-
rence of ubiquinones-8 and 9 in Plasmodium lophurae 
and the identification of ubiquinone-8 biosynthesised by 
P. knowlesi, Plasmodium cynomolgi, and Plasmodium 
berghei. Afterwards, Mbaya et al. (1990) showed that 
schizont extracts of P. falciparum biosynthesised isopre-
noid until the farnesyl pyrophosphate step upon incuba-
tion with [14C]mevalonate. Using [14C]acetate, they also 
demonstrated that the isoprenoid metabolism appeared 
to be stage-dependent, which was shown by the increase 
in radiolabelled farnesyl pyrophosphate at the beginning 
of the schizogonic phase. 
Several glycoconjugates, biosynthesised by the in-
traerythrocytic stages of P. falciparum, use dolichol and 
its phosphorylated derivatives as carrier lipids. Anchors 
and N-linked glycoproteins require dolichyl phosphate 
and dolichyl pyrophosphate as carriers of different mono- 
saccharide constituents (Schwarz & Datema 1982). 
Kimura et al. (1996) demonstrated the effect of N-linked 
glycoproteins on differentiation of intraerythrocytic 
stages of P. falciparum. Walter (1986) demonstrated the 
presence of dolichol kinase, a rate-limiting enzyme for 
the supply of dolichyl pyrophosphate, in P. falciparum. 
Many eukaryotic cells, such as yeast and a number of 
mammalian cells, are unable to incorporate more com-
plex isoprenoid precursors such as [3H]FPP and [3H]
GGPP. In contrast, intraerythrocytic forms of P. falci-
parum easily metabolise these compounds when they are 
added to the culture medium, permitting the subsequent 
identification of higher isoprenoids. Accordingly, Couto 
et al. (1999) identified dolichol, dolichyl phosphate and 
dolichyl pyrophosphate of 55 and 60 carbons (11/12 iso-
prenic units) by metabolic labelling of parasites with 
[3H]FPP and [3H]GGPP in different intraerythrocytic 
stages of P. falciparum. This study was the first dem-
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onstration of short-chain dolichols in the phylum Api-
complexa. Despite the fact that few reports exist on the 
characterisation of dolichols in protozoans, the presence 
of short-chain isoprenoid species seems to be a common 
feature. Dolichols of 13 isoprene units in Trypanosoma 
cruzi (Parodi & Quesada-Allue 1982), of 11 isoprene 
units in Crithidia fasciculata (Quesada-Allue & Parodi 
1983) and of 11 and 12 isoprene units in Trypanosoma 
brucei (Low et al. 1991) have been reported. 
The biosynthetic pathways for cholesterol, dolichol 
and ubiquinones share the same initial steps. Using 
[1-14C]acetate and 3H2O as labelling precursors, Vial et 
al. (1984) showed that cholesterol synthesis in P. falci-
parum was almost undetectable, in accordance with very 
low levels of measurable HMG-CoA reductase activity.
In P. falciparum, the biosynthesis of ubiquinone 
or coenzyme Q involves two major steps: synthesis of 
the benzoquinone by the shikimate pathway and syn-
thesis of the isoprene side chain by the MEP pathway. 
The biosynthesis and regulation of coenzyme Q was 
also studied in protozoans. T. brucei and Leishmania 
major synthesise the polyprenyl side of ubiquinone via 
the mevalonate pathway (Low et al. 1991, Ranganathan 
& Mukkada 1995). Coenzyme Q8 and coenzyme Q9 
were detected in P. falciparum using [14C]PHBA to la-
bel the benzoquinone ring in parasite-infected blood 
from Aotus trivirgatus monkeys (Schnell et al. 1971). de 
Macedo et al. (2002) demonstrated that P. falciparum 
has an active isoprenoid pathway for the biosynthesis 
of the isoprenic chain of coenzyme Q. Additionally, P. 
falciparum is able to synthesise different homologues 
of this molecule depending on the given intermediate. 
When labelling was performed with [3H]FPP, coenzyme 
Q with an isoprenic chain of 40 carbons (Q8) was detect-
ed, whereas labelling with [3H]GGPP resulted in Q9 (45 
carbons) moieties. These authors also demonstrated that 
nerolidol treatment of P. falciparum parasites results in 
a reduced ability to synthesise CoQ and inhibits P. falci-
parum growth in vitro. Rodrigues Goulart et al. (2004) 
demonstrated that terpenes (farnesol, nerolidol and li-
nalool) exert an inhibitory effect on the biosynthesis 
of the isoprenic side chain of the benzoquinone ring of 
Isoprenoids biosynthesised by Plasmodium falciparum. IPP and DMAPP are biosynthesised by MEP. Steps that are engineered to improve 
isoprenoid compound production as described in the text are highlighted. The enzymes of this pathway that were characterised in P. falciparum 
are represented in white boxes and the corresponding inhibitors are in circles. In subsequent steps, IPP and DMAPP are utilised by prenyltrans-
ferases to produce a variety of linear allylic prenyl diphosphates of increasing size. GPP C10, FPP C15 and GGPP C20 are intermediates for the 
synthesis of the wide range of end products derived from the isoprenoid pathway. The shaded boxes indicate the isoprenics compounds currently 
characterised in P. falciparum by our group. The inhibitor of each isoprenic product is indicated in circles. In the white box, the bi-functional 
enzyme octaprenyl pyrophosphate synthase (OPPs)/phythoene synthase (PfB0130w) is represented.
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ubiquinones in the schizont stages. Also, these authors 
showed that all of these terpenes inhibited dolichol bio-
synthesis in trophozoite and schizont stages when [3H]
FPP was used as a precursor (Figure).
Octaprenyl pyrophosphate synthase (OPPs) belongs 
to a prenyl transferase family, which catalyses the con-
densation reactions of FPP with five molecules of IPP to 
produce C40 OPP (Guo et al. 2004). OPP enzymes are 
responsible for the biosynthesis of side chains attached 
to ubiquinones in E. coli (Okada et al. 1996). Signifi-
cant differences occur in the length of the isoprenic side 
chains of ubiquinones from different organisms, sug-
gesting that specific prenyltransferases are involved in 
the synthesis of these side chains. For example, the sizes 
of the ubiquinone side chain are C30 in Saccharomyces 
cerevisiae, C45 in rats and C50 in humans, and these 
are synthesized by hexaprenyl pyrophosphate synthase, 
solanesyl pyrophosphate synthase and decaprenyl py-
rophosphate synthase respectively (Ashby & Edwards 
1990, Teclebrhan et al. 1993). In P. falciparum, the iso-
prenic side chains of ubiquinone contain eight or nine 
isoprenic units, unlike humans, which contain 10 iso-
prenic units. These length differences of the isoprenoid 
side-chain compounds encountered in humans and the 
malaria parasite P. falciparum could possibly be exploit-
ed as drug targets (de Macedo et al. 2002).
Tonhosolo et al. (2005) demonstrated the existence of 
OPPs activity in P. falciparum, and the recombinant pro-
tein showed an OPP activity producing polyisoprenoids 
with eight isoprenic units from FPP and IPP as substrate. 
The transcription of PfOPPs was found to occur in the 
ring and trophozoite stages, while the polypeptide was 
mainly found in the schizont stages. These authors also 
showed that the recombinant enzyme could be competi-
tively inhibited in the presence of the terpene nerolidol, 
which has a chemical structure that resembles the sub-
strate FPP. These data suggest that nerolidol inhibits the 
biosynthesis of dolichol, thereby supporting earlier con-
clusions from de Macedo et al. (2002). Considering the 
differences in the length of isoprenic side chains in P. 
falciparum and humans, nerolidol could be exploited as 
a potential drug in malaria (Figure).
Our group has previously demonstrated that intra- 
erythrocytic stages of P. falciparum biosynthesise certain 
unknown polyisoprenic compounds when [3H]GGPP 
was used as a metabolic precursor (Couto et al. 1999). 
Taking into account that plant and algae plastids are sites 
for polyisoprenoid synthesis including carotenes, we in-
vestigated the possibility that P. falciparum was also 
able to produce carotenoids because carotenoids have 
GGPP as a precursor in other organisms.
The chemical characteristics and physical properties 
of carotenoids are responsible for their abilities to ab-
sorb light, scavenge free radicals and act as antioxidants, 
which are essential during photosynthesis. Tonhosolo et 
al. (2009) showed for the first time that the biosynthesis of 
carotenoids is functionally active in the intraerythrocytic 
stages of P. falciparum, representing another “plant-like” 
pathway present in these parasites. In this work, we de-
tected that the full-length version of the previously de-
scribed PfOPPs also exerted phytoene synthase activity. 
Accordingly, norflurazon, a well-known bleaching herbi-
cide that inhibits carotenoid biosynthesis in higher plants 
and microalgae, inhibited in vitro growth of P. falci-
parum. This inhibition could be partially reversed by the 
addition of lycopene, a downstream product in the caro-
tenoid pathway. The function of carotenoid in the malaria 
parasite is unknown. However, in T. gondii, Nagamune 
et al. (2008) demonstrated the biosynthesis of phytohor-
mone abscisic acid, a final product of the biosynthesis of 
carotenoid, which controls calcium signalling within the 
apicomplexan parasite. Because carotenoid biosynthesis 
is absent in humans, this pathway might also be exploited 
as a new target for antimalarial drugs.
Vitamins are essential components of the human 
diet. By contrast, the malaria parasite P. falciparum and 
related apicomplexan parasites synthesise certain vita-
mins de novo, either completely or in part, highlighting 
the parasite’s distinct requirements for nutrients and 
growth factors. Furthermore, the lack of these pathways 
in the mammalian host implies that inhibition of the 
parasite pathways might be exploitable for the design of 
new antimalarials. The MEP and shikimate pathways 
supply the precursors for biosynthesis of vitamin K2 or 
MQ in bacteria and phylloquinone in plants, algae and 
cyanobacteria. In P. falciparum, Tonhosolo et al. (2010) 
showed that the intraerythrocytic stages have an active 
pathway for the biosynthesis of MQ-4 and demonstrated 
that MQ could replace the physiological function of ubi-
quinone under anaerobic conditions. Many respiratory 
enzymes from E. coli can use MQ and ubiquinone as 
substrates depending on the oxygen supply in the envi-
ronment, whereas mammals have only ubiquinone. P. 
falciparum can be regarded as microaerophilic during 
its asexual intraerythrocytic life cycle. Tonhosolo et al. 
(2010) showed that P. falciparum can change the content 
of the quinone pools depending on the aeration condi-
tion. Additionally, they showed that the mycobacterial 
inhibitor of MQ synthesis (Ro48-8071) suppressed MQ 
biosynthesis and parasite growth (Figure).
Post-translational modification of proteins with iso-
prenoids was first recognised as a general phenomenon 
in 1984 (Schmidt et al. 1984). The isoprenyl group is 
bound post-translationally to cysteine residues at the C-
terminus of proteins through a thioether bond. Studies 
have shown that FPP (15 carbons) and GGPP (20 carbons) 
are the most common isoprenoids attached to proteins. 
Several of the proteins that undergo these modifications 
have been identified and many participate in important 
cell regulatory functions, particularly signal transduction 
pathways (Zhang & Casey 1996). Protein prenylation is a 
general phenomenon in eukaryotic cells and has been de-
scribed for several protozoan parasites (Lujan et al. 1995, 
Field et al. 1996, Shen et al. 1996, Ibrahim et al. 2001), 
including P. falciparum (Chakrabarti et al. 2002).
Families of Rab G-protein and Ras-related proteins 
have been characterised in P. falciparum (de Castro 
et al. 1996, Jambou et al. 1996) and Chakrabarti et al. 
1998, 2002) reported the identification of protein far-
nesyl transferase (PFT) and protein geranylgeranyl 
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transferase-I activities in all stages of intraerythrocytic 
P. falciparum. Prenylation might occur in multiple com-
partments, but none of the P. falciparum prenyl trans-
ferases possess apicoplast-targeting signals and prenyl 
transferase activity has been detected only in cytosolic 
fractions. Additionally, peptidomimetics and prenyl an-
alogues could inhibit PFT purified from parasites and 
malaria parasite growth. The presence of isoprenylated 
proteins has been demonstrated by metabolic labelling 
in T. gondii (Ibrahim et al. 2001).
Moura et al. (2001) characterised proteins with iso-
prenic groups by metabolic labelling with [3H]FPP and 
[3H]GGPP. In the same work, treatment of parasites with 
limonene, an inhibitor of prenyl transferase, inhibited 
parasite growth by delaying maturation from ring to tro-
phozoite stages and decreased the incorporation of the 
isoprenic group in proteins. 
Later, Rodrigues Goulart et al. (2004) demonstrated 
that terpenes (farnesol, nerolidol, limonene and lina-
lool) and S-farnesylthiosalicylic acid led to a decrease 
in the amount of isoprenylated proteins in P. falciparum 
schizont stages. Recently, Jordão et al. (2011) characterised 
the antiplasmodial activity of risedronate in vitro and 
in vivo and demonstrated that risedronate inhibits the 
transfer of the farnesyl pyrophosphate group to parasite 
proteins coinciding with parasite growth inhibition in 
vitro. In vivo treatment with risedronate led to an 88.9% 
inhibition of the rodent parasite P. berghei in mice on the 
seventh day of treatment; however, no general increase 
in survival rates was achieved.
Another type of protein modification is the at-
tachment of a dolichyl group to proteins. This type of 
modification is characterised by covalently and post-
translationally bound dolichyl groups to the C-terminal 
cysteine residues of proteins. The protein dolichylation 
was described in tumour cells and dolichylated proteins 
are possibly involved in cell cycle control (Hjertman et 
al. 1997). In P. falciparum, dolichylated proteins with 
11 isoprenic units were found attached to 21 and 28 kDa 
sized proteins. The purpose of dolichylation of proteins 
in P. falciparum is currently unknown. Because the 
dolichylated protein species appear predominantly dur-
ing the replication phase of the parasite (schizogony) 
(D’Alexandri et al. 2006), one may speculate that its 
involvement in cell cycle control is similar to that in tu-
mour cells (Hjertman et al. 1997).
Final comments - Despite all of the recent progress 
in the understanding of the synthesis and the detection 
of unexpected metabolic intermediates such as phy-
toene, many questions still remain unanswered. For ex-
ample, what purpose do carotenes have in the life cycle 
of Plasmodium? What are proteins modified with iso-
prenic residues and at which point in the metabolism of 
Plasmodium do they exert their function? The answers 
for these questions may reveal not only novel aspects of 
this evolutionarily special parasite group but also novel 
points of chemotherapeutic intervention.
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